blue-20240424

0001293971-24-000014.txt : 20240426 0001293971-24-000014.hdr.sgml : 20240426 20240426160837 ACCESSION NUMBER: 0001293971-24-000014 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240424 ITEM INFORMATION: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240426 DATE AS OF CHANGE: 20240426 FILER: COMPANY DATA: COMPANY CONFORMED NAME: bluebird bio, Inc. CENTRAL INDEX KEY: 0001293971 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35966 FILM NUMBER: 24883702 BUSINESS ADDRESS: STREET 1: 455 GRAND UNION BOULEVARD CITY: SOMERVILLE STATE: MA ZIP: 02145 BUSINESS PHONE: 339-499-9300 MAIL ADDRESS: STREET 1: 455 GRAND UNION BOULEVARD CITY: SOMERVILLE STATE: MA ZIP: 02145 FORMER COMPANY: FORMER CONFORMED NAME: Genetix Pharmaceuticals Inc DATE OF NAME CHANGE: 20040616 8-K 1 blue-20240424.htm 8-K blue-20240424

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

__________________________

FORM 8-K

__________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 24, 2024

__________________________

bluebird bio, Inc.

(Exact name of Registrant as Specified in Its Charter)

_____________________________________________________________


Delaware	001-35966	13-3680878
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

455 Grand Union Boulevard, Somerville, MA		02145
(Address of Principal Executive Offices)		(Zip Code)

(339) 499-9300

(Registrant’s telephone number, including area code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

_____________________________________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):


☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.01 par value per share	BLUE	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐


Item 3.01			Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On April 24, 2024, bluebird bio, Inc. (the “Company”) received a notification letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, as a result of the Company's delay in filing its Annual Report on Form 10-K for the year ended December 31, 2023 (the “2023 Form 10-K”) with the Securities and Exchange Commission (the “SEC”), the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Rule”), which requires Nasdaq-listed companies to timely file all required periodic financial reports with the SEC.

The Notice states that the Company has 60 calendar days from the date of the Notice, or until June 24, 2024, to submit a plan to regain compliance with the Rule. If Nasdaq accepts the Company's plan to regain compliance, then Nasdaq may grant the Company up to 180 calendar days from the prescribed due date of its 2023 Form 10-K, or until October 14, 2024, to file its 2023 Form 10-K to regain compliance with the Rule. The Notice has no immediate effect on the listing of the Company's securities on Nasdaq.

As previously reported, the delay in filing the 2023 Form 10-K is due to the need to restate the Company’s consolidated financial statements as of and for the year ended December 31, 2022 and unaudited financial information for each of the first three quarters of 2023 and 2022 in its 2023 Form 10-K. The Company requires additional time to complete all necessary procedures in connection with the restatements. The Company intends to submit a plan to regain compliance with the Rule prior to June 24, 2024 and to file the 2023 Form 10-K with the SEC as promptly as possible.


Item 7.01			Regulation FD Disclosure.

On April 26, 2024, the Company issued a press release in accordance with Nasdaq Listing Rule 5810(b) announcing that the Company had received the Notice. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information furnished under this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference into any of the Company’s filings under the Securities Act of 1933, as amended, or the Securities Act, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing.

Forward-Looking Statements

This Current Report contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this Current Report that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding the Company’s expectations with respect to the filing of the Company’s 2023 Form 10-K and submitting a plan to regain compliance with the Rule. Statements using words such as “expect”, “anticipate”, “believe”, “may”, “will” and similar terms are also forward-looking statements. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the important factors discussed under the caption “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, as updated by its subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the Securities and Exchange Commission. Except as required by law, the Company undertakes no obligations to make any revisions to the forward-looking statements contained in this Current Report or to update them to reflect events or circumstances occurring after the date of this Current Report, whether as a result of new information, future developments or otherwise.


Item 9.01			Financial Statements and Exhibits.

(d) Exhibits


Exhibit No.						Description
99.1						Press release issued by bluebird bio, Inc. on April 2 6 , 2024.
104						Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.



Date: April 26, 2024	bluebird bio, Inc.

	By:	/s/ Christopher Krawtschuk
	Name:	Christopher Krawtschuk
	Title:	Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer

EX-99.1 2 exhibit99120240424.htm EX-99.1 Document

Exhibit 99.1

bluebird bio Announces Receipt of Expected Notice from Nasdaq

SOMERVILLE, Mass.--(BUSINESS WIRE)—April 26, 2024-- bluebird bio, Inc. (Nasdaq: BLUE) today announced that it received a notice (the “notice”) on April 24, 2024 from The Nasdaq Stock Market LLC (“Nasdaq”) stating that because the Company has not yet filed its Annual Report on Form 10-K for the year ended December 31, 2023 (the “2023 Form 10-K"), it is no longer in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Rule”), which requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission (the “SEC”).

The notice has no immediate effect on the listing or trading of the Company’s common stock on the Nasdaq. Under Nasdaq rules, the Company has 60 calendar days from receipt of the notice, or until June 24, 2024, to submit a plan to regain compliance with the Rule.

On April 16, 2024, bluebird previously announced that it would be delayed in filing its 2023 Form 10-K due to the need to restate the Company’s consolidated financial statements as of and for the year ended December 31, 2022 and unaudited financial information for each of the first three quarters of 2023 and 2022 in its 2023 Form 10-K. The notice from Nasdaq is standard practice in the event of a delayed 10-K filing and was anticipated.

The Company is continuing to work expeditiously to complete the filing of the 2023 Form 10-K as promptly as possible. As previously reported, the restatements relate to the identification of embedded leases and the treatment of non-lease components contained in lease agreements. The Company does not expect the restatements to result in any impact on its cash position or revenue.

About bluebird bio, Inc.

bluebird bio is pursuing curative gene therapies to give patients and their families more bluebird days.

Founded in 2010, bluebird has been setting the standard for gene therapy for more than a decade—first as a scientific pioneer and now as a commercial leader. bluebird has an unrivaled track record in bringing the promise of gene therapy out of clinical studies and into the real-world setting, having secured FDA approvals for three therapies in under two years. Today, we are proving and scaling the commercial model for gene therapy and delivering innovative solutions for access to patients, providers, and payers.

With a dedicated focus on severe genetic diseases, bluebird has the largest and deepest ex-vivo gene therapy data set in the field, with industry-leading programs for sickle cell disease, β-thalassemia and cerebral adrenoleukodystrophy. We custom design each of our therapies to address the underlying cause of disease and have developed in-depth and effective analytical methods to understand the safety of our lentiviral vector technologies and drive the field of gene therapy forward.

bluebird continues to forge new paths as a standalone commercial gene therapy company, combining our real-world experience with a deep commitment to patient communities and a people-centric culture that attracts and grows a diverse flock of dedicated birds.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements that are not statements of historical facts are, or may be deemed to be, forward-looking statements, such as statements regarding the Company’s restatement of certain historical financial statements and impact on cash position and revenue, the filing of its 2023 Form 10-K and submission of a plan to regain compliance with the Rule. Such forward-looking statements are based on historical performance and current expectations and projections about bluebird’s future goals, plans and objectives and involve inherent risks, assumptions and uncertainties, including internal or external factors that could delay, divert or change any of them in the next several years, that are difficult to predict, may be beyond bluebird’s control and could cause bluebird’s future goals, plans and objectives to differ materially from those expressed in, or implied by, the statements. No forward-looking statement can be guaranteed. Forward-looking statements in this press release should be evaluated together with the many risks and uncertainties that affect bluebird bio’s business, particularly those identified in the risk factors discussion in bluebird bio’s Annual Report on Form 10-K for the year ended December 31, 2022, as updated by its subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the SEC. The forward-looking statements included in this document are made only as of the date of this document and except as otherwise required by applicable law, bluebird bio undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise.

Investors:

Courtney O’Leary, 978-621-7347
coleary@bluebirdbio.com

Media:

Jess Rowlands, 857-299-6103
jess.rowlands@bluebirdbio.com

EX-101.SCH 3 blue-20240424.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 blue-20240424_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Security Exchange Name Security Exchange Name Title of 12(b) Security Title of 12(b) Security Written Communications Written Communications Local Phone Number Local Phone Number Trading Symbol Trading Symbol Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, State or Province Entity Address, State or Province Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Document Period End Date Document Period End Date Cover page. Cover [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Pre-commencement Tender Offer Pre-commencement Tender Offer Soliciting Material Soliciting Material City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Document Type Document Type Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Entity File Number Entity File Number Entity Address, City or Town Entity Address, City or Town Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Registrant Name Entity Registrant Name EX-101.PRE 5 blue-20240424_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 7 R1.htm IDEA: XBRL DOCUMENT

Cover	Apr. 24, 2024
Cover [Abstract]
Document Type	8-K
Document Period End Date	Apr. 24, 2024
Entity Registrant Name	bluebird bio, Inc.
Entity Incorporation, State or Country Code	DE
Entity File Number	001-35966
Entity Tax Identification Number	13-3680878
Entity Address, Address Line One	455 Grand Union Boulevard
Entity Address, City or Town	Somerville
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02145
City Area Code	339
Local Phone Number	499-9300
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock, $0.01 par value per share
Trading Symbol	BLUE
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	false
Entity Central Index Key	0001293971
Amendment Flag	false

EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( !&!FE@'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " 1@9I80A?2/.X K @ $0 &1O8U!R;W!S+V-O&ULS9+/ M2L0P$(=?17)O)_W#(J&;B^))07!!\1:2V=U@TX1DI-VWMXV[740?P&-F?OGF M&YA.!Z%]Q.?H T:RF&XFUP])Z+!E1Z(@ )(^HE.IG!/#W-S[Z!3-SWB H/2' M.B#4G&_ (2FC2,$"+,)*9+(S6NB(BGP\XXU>\>$S]AEF-&"/#@=*4)45,+E, M#*>I[^ *6&"$T:7O IJ5F*M_8G,'V#DY);NFQG$LQR;GYATJ>'MZ?,GK%G9( MI :-\Z]D!9T";MEE\FMS=[][8++F=5OPMJ@WNYH+?BN:]GUQ_>%W%7;>V+W] MQ\870=G!K[N07U!+ P04 " 1@9I8F5R<(Q & "<)P $P 'AL+W1H M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X M8-DOV]:[MR_>X%#BVR]*+ M41B1%G\@M MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7 MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V< M/!T3$LV4"P9!AI@S M&L%&KQMUAVC2/'K^!?F<-0HACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0' MHYI9";V$5FJ?JH,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RSTS0LS0[=R2^JVE+ZU)CA* M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D* MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-# MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P MOFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2 MD 83 >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+ M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5 M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0 ( M !&!FEC82AL!2 0 ($0 8 >&PO=V]R:W-H965T&UL ME9AO;^HV%,:_BI5-TR:5Y@^!0@=(E+9WU6U[66EWI4U[81(#5A,[UW:@?/L= M!TB8;CCAOFGB).?A9Y_CQW8'&ZG>]8HQ0S[21.BALS(FNW9=':U82O6ES)B M-PNI4FJ@J9:NSA2C<1&4)F[@>5TWI5PXHT'Q;*I& YF;A LV543G:4K5]H8E M#C"[9C)FW;*J@Y98J,4^9T%P*HMABZ(S]ZYL@M '% M%W]QMM%']\1V92[ENVT\Q$/'LT0L89&Q$A0N:S9A26*5@./;7M0I?],&'M\? MU.^+SD-GYE2SB4R^\MBLAD[/(3%;T#PQ+W+S!]MWJ&/U(IGHXB_9[+X-0X=$ MN38RW0<#0*Z-@D3]6T>T4PCK%6SU7NN,1FSH0'EJIM;,&?WRD]_U M?D?XVB5?&U,?W![$E"DN8W(G8@))K^7! ME6O4Z)U4,$[8;C9DA>VY#:#P/A,TUHP7&>>Y&S.54SF7%Z0!Q%=(G#= M$JY[#ARH295)1:T=7)"9@:$C4I&)S(516[C&M<2X^.T=0GA5$EZ=0WC/$T:> M\W1>/R5Q#<_S6^U.O]M%>'HE3^\:-S!.VIBI& M:'VO\ECOAW@GM@65]RHWHM9[<;F93,'>>)(PC.YH!?!_B*Z<&%,EUUQ$M!O-KM[%@(H8MT)?%XD3^<+U&LLKZ?=RIOR-[T#H'LD9 7+81L#)_'_?J M5VY@F90+X@>_SG\C,Q;E4&_;6B9W8[_Q)B.MO]G&?T=+&Q+.TJ?0,&LK(%D5-2FMD&PJ=R"RN<# MW*;W:!.8"@I\]@%FP0?YS.JA<"D/]FA!O]V_\C&RROB#AET\3,^XF*+W"5W6 M\N ")P?)/3I0VL/Y$[5IT21A"Q#R+J_ MM7NO+MK&)D59\RY-'!B+6Y7C()? MV _@_4)*6QEO%DN7/ZZZ>S;"=I=67=A['-HN6/O.-%Q[I#)6,>=56R=M8SDK6W!2,EG>W&2)8D+38JT[=:=<2PZF MTVY#;VA2K"NCSY:4!H-?RA0GCTQNZ)9)L;=B6,N4D*=@7H+A8*2QQ'DJ?$,7 M8&F? KP(&K XU7=>&18/ MQA<0&>7=J?$,:\M.B^4M/3L,/S[)WMB2VSG-@DZF8BUY!72LJ(_PZTR3 .B< M45XH!:N-9@.'R6,4?-@#E_(!6OBMNHK=5R3TXE,);2"PU4GTA$8QA D*Q+^, M%F)?A+W]K;"D$8_&?>S\;O2@?^^,X_>65Z(?]+Z:\V/1%WATUC3R]$&*6BL> M]O[+"8LUF_S(T5CQY+/!I!R\@5M*'KEUXG!I^6%9L^.]FZ:IKW#.RW^0\Y^M M<\TUMTQ>DO:C_S=7^2V,D_'T7!S1JP,Z6PEY7>>9 ]IV03NA1.XJR MY/K%.?7A'=O["_PJOE]?\HIUTNUF<$//\A=>BD[E\ZI[J,NXZBQ_AOMHD\%G'!QR>(W?#$T%^@2O&+(=/EB>N$_NG_A.\SQ-LPRKZ'8;9;#%ZI9E\!>/ MAG$##RP/9'I;K?%NXQ/R^AQ@/7UM0K"=XI.([12O-2#QNH%'GL>[C>4!#ZP+ MV.Q _G@>F*FX3YI"5S%NV G&D3S'$)C%^(QF&5*=##[Q_F"G)$WS/(X %F>0 MIA@"IQ%', ; 4/2='@//GL?)=-[*CG_5U/\!%!+ P04 " 1@9I8EXJ[ M', 3 @ "P %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">, ?0(8@S9?$6 M!/D!5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]$%)I6M6X 4BV M)8]ISI%"KM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D5XA-/E_G;@2=&A(E@6FD7)TZ(= MI7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0 ( M !&!FEBJQ"(6,P$ "(" / >&PO=V]R:V)O;VLN>&ULC5'1;L(P#/R5 M*A^P%K0A#5%>0-N0I@V-B??0NM0BB2O'A8VOG]NJ&M)>]I31=B;FJ19IZFL:C!VWA'#02=5,3>BD(^IK%AL&6L <2[=)IEL]1;#&:Y M&+6VG-X"$B@$*2C9$7N$2_R==S Y8\0#.I3OW/1W!R;Q&-#C% MB/%*0:S;%4S.Y68R#/; @L4?>M>9_+2'V#-B#Q]6C>1FEJE@A1REW^CUK7H\ M@RX/J!5Z0B? :ROPS-0V&(Z=C*9(;V+T/8SG4.*<_U,C5146L*:B]1!DZ)'! M=09#K+&))@G60VY6= ;N\N@#FW+()FKJIBF>HPYX4P[V1D\E5!B@?%.9J+SV M4VPYZ8Y>9WK_,'G4'EKG5LJ]AU>RY1AQ_)[E#U!+ P04 " 1@9I8)!Z; MHJT #X 0 &@ 'AL+U]R96QS+W=O[IFB MG#S^0W1UW6E\./VR./ /,+Q=Z*E%9"E*%1KD3,)HMC;!4N++3):BJ#(9BBJ6 M<%H@XLD@;6E6?;!/3K3G>1,)KM\,<'AT_@%02P,$% @ $8&: M6&60>9(9 0 SP, !, !;0V]N=&5N=%]4>7!E&ULK9--3L,P$(6O M$F5;)2XL6*"F&V +77 !8T\:J_Z39UK2VS-.VDJ@$A6%3:QXWKS/GI>LWH\1 ML.B=]=B4'5%\% )5!TYB'2)XKK0A.4G\FK8B2K636Q#WR^6#4,$3>*HH>Y3K MU3.T.EY&TWP39G 8ED\C<+,:DH9HS5*$M?%P>L?E.I$J+EST&!G(BY8 M4(JKA%SY'7#J>SM 2D9#L9&)7J5CE>BM0#I:P'K:XLH90]L:!3JHO>.6&F," MJ;$#(&?KT70Q32:>,(S/N]G\P68*R,I-"A$YL01_QYTCR=U59"-(9*:O>"&R M]>S[04Y;@[Z1S>/]#&DWY(%B6.;/^'O&%_\;SO$1PNZ_/[&\UDX:?^:+X3]> M?P%02P$"% ,4 " 1@9I8!T%-8H$ "Q $ @ $ M 9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0 ( !&!FEA"%](\[@ "L" M 1 " :\ !D;V-0&UL4$L! A0#% @ $8&:6-A*&P%(! @1 !@ M ("!#0@ 'AL+W=O7!E&UL4$L%!@ ) - D /@( -\3 $! end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.u1 html 1 22 1 false 0 0 false 0 false false R1.htm 0000001 - Document - Cover Sheet http://www.bluebirdbio.com/role/Cover Cover Cover 1 false false All Reports Book All Reports blue-20240424.htm blue-20240424.xsd blue-20240424_lab.xml blue-20240424_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "blue-20240424.htm": { "nsprefix": "blue", "nsuri": "http://www.bluebirdbio.com/20240424", "dts": { "inline": { "local": [ "blue-20240424.htm" ] }, "schema": { "local": [ "blue-20240424.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "blue-20240424_lab.xml" ] }, "presentationLink": { "local": [ "blue-20240424_pre.xml" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 23, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "report": { "R1": { "role": "http://www.bluebirdbio.com/role/Cover", "longName": "0000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "blue-20240424.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "blue-20240424.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cover page.", "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Issuer Tender Offer", "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Tender Offer", "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Soliciting Material", "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.bluebirdbio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Written Communications", "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 15 0001293971-24-000014-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001293971-24-000014-xbrl.zip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end XML 17 blue-20240424_htm.xml IDEA: XBRL DOCUMENT 0001293971 2024-04-24 2024-04-24 0001293971 false 8-K 2024-04-24 bluebird bio, Inc. DE 001-35966 13-3680878 455 Grand Union Boulevard Somerville MA 02145 339 499-9300 false false false false Common Stock, $0.01 par value per share BLUE NASDAQ false